Core Viewpoint - Investors are seeking growth stocks that can deliver above-average growth and exceptional returns, but identifying such stocks can be challenging due to inherent risks and volatility [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system helps identify promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - Global Partners LP (GLP) is currently recommended due to its favorable Growth Score and top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth indicating strong prospects [3] - Global Partners has a historical EPS growth rate of 12%, but projected EPS growth for this year is 23.2%, significantly higher than the industry average of 10.7% [4] Group 3: Asset Utilization - The asset utilization ratio, or sales-to-total-assets (S/TA) ratio, is an important indicator of efficiency in generating sales [5] - Global Partners has an S/TA ratio of 4.74, indicating it generates $4.74 in sales for every dollar in assets, compared to the industry average of 0.97 [6] Group 4: Sales Growth - The company is expected to achieve a sales growth of 37.2% this year, while the industry average is 0% [6] Group 5: Earnings Estimate Revisions - Positive trends in earnings estimate revisions correlate strongly with near-term stock price movements [7] - The current-year earnings estimates for Global Partners have increased by 4.6% over the past month [8] Group 6: Overall Positioning - Global Partners holds a Zacks Rank of 2 and a Growth Score of B, positioning it well for potential outperformance in the growth stock category [10]

Core Viewpoint - The healthcare sector is facing volatility due to President Trump's tariff threat on imported pharmaceuticals, which has led to a 2.74% decline in the sector over the past week and a 5.13% loss year-to-date, the worst among all S&P 500 sectors [1] Company-Specific Insights - Novo Nordisk experienced a 5.79% decline in stock price over the past five days following disappointing earnings, but rebounded due to weak trial data from Eli Lilly, which saw its shares drop nearly 11% [2] - Eli Lilly reported strong demand for its anti-obesity drugs, Mounjaro and Zepbound, despite a recent stock decline of 14.49% this year [9][15] - Novo Nordisk's Q2 revenue was $11.95 billion, slightly below expectations, but it reported a 16% increase in sales for its diabetes drug Ozempic and weight loss drug Wegovy compared to the previous year [10] Industry Trends - The Trump administration's initiative to cover weight loss drugs under Medicare and Medicaid could significantly increase access to these medications, potentially benefiting Eli Lilly and Novo Nordisk [5][8] - The global weight loss drug market is projected to grow at a compound annual growth rate of 31.66% from 2024 to 2030, with North America currently holding a 37.67% revenue share [13][14] - The U.S. anti-obesity drug market is valued at $6.62 billion and is expected to reach $7.13 billion by 2030 [14]

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) The unaudited financial statements show a slight asset decrease, with six-month net income and operating cash flow significantly improving year-over-year [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) Total assets slightly decreased to **$3.78 billion**, while liabilities increased and partners' equity declined as of June 30, 2025 Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | Change | | :--- | :--- | :--- | :--- | | **Total current assets** | $1,215,163 | $1,207,380 | $7,783 | | Property and equipment, net | $1,668,367 | $1,706,605 | ($38,238) | | **Total assets** | **$3,784,338** | **$3,788,198** | **($3,860)** | | **Total current liabilities** | $1,027,264 | $1,000,121 | $27,143 | | Senior notes | $1,270,916 | $1,186,723 | $84,193 | | **Total liabilities** | **$3,098,033** | **$3,071,585** | **$26,448** | | **Total partners' equity** | **$686,305** | **$716,613** | **($30,308)** | [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Q2 2025 sales increased but net income decreased, while six-month sales and net income both improved year-over-year Consolidated Statements of Operations Summary (in thousands, except per unit data) | Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 | | :--- | :--- | :--- | :--- | :--- | | Sales | $4,626,925 | $4,409,698 | $9,219,122 | $8,555,090 | | Gross Profit | $272,362 | $287,884 | $527,603 | $503,019 | | Operating Income | $60,066 | $83,869 | $115,953 | $109,705 | | Net Income | $25,210 | $46,149 | $43,894 | $40,547 | | Diluted EPS | $0.55 | $1.10 | $0.92 | $0.73 | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow significantly improved to a provision of **$164.7 million**, while investing and financing activities shifted due to acquisitions and debt refinancing Six Months Ended June 30, Cash Flow Summary (in thousands) | Cash Flow Category | 2025 | 2024 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $164,730 | ($158,356) | | Net cash used in investing activities | ($44,435) | ($232,174) | | Net cash (used in) provided by financing activities | ($112,406) | $385,002 | | **Increase (decrease) in cash and cash equivalents** | **$7,889** | **($5,528)** | [Notes to Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) Detailed notes cover accounting policies, significant 2025 events including debt refinancing and credit agreement amendments, and segment performance - In June 2025, the Partnership issued **$450.0 million** of 7.125% senior notes due 2033, using proceeds to redeem 2027 notes and repay credit facility borrowings[20](index=20&type=chunk)[21](index=21&type=chunk) - The credit agreement was amended in March 2025, extending maturity to March 2028, increasing the working capital facility to **$1.0 billion**, and decreasing the revolving credit facility to **$500.0 million**[22](index=22&type=chunk)[47](index=47&type=chunk) - The Gasoline Distribution and Station Operations (GDSO) segment is the largest contributor to product margin, accounting for **68%** and **67%** of the consolidated total in Q2 and H1 2025, respectively[31](index=31&type=chunk) Cash Distributions Paid in 2025 (in thousands, except per unit data) | Payment Date | Security | Quarter Ended | Per Unit | Total Paid | | :--- | :--- | :--- | :--- | :--- | | 2/14/2025 | Common Units | 12/31/24 | $0.7400 | $29,483 | | 5/15/2025 | Common Units | 03/31/25 | $0.7450 | $29,815 | | 2/18/2025 | Series B Preferred | 11/15/24 - 2/14/25 | $0.59375 | $1,781 | | 5/15/2025 | Series B Preferred | 2/15/25 - 5/14/25 | $0.59375 | $1,781 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=55&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses increased sales driven by volume, a Q2 gross profit decline due to market conditions, and key financing activities impacting liquidity [Results of Operations](index=66&type=section&id=Results%20of%20Operations) Q2 sales increased but gross profit declined due to gasoline margins, while H1 sales and gross profit grew, with SG&A expenses rising Gross Profit by Period (in millions) | Period | Q2 2025 | Q2 2024 | Change | H1 2025 | H1 2024 | Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Gross Profit | $272.4 | $287.9 | -5% | $527.6 | $503.0 | +5% | - Wholesale segment product margin decreased by **16%** in Q2 2025 for gasoline due to unfavorable market conditions, but increased by **53%** for distillates due to more favorable conditions[227](index=227&type=chunk)[230](index=230&type=chunk) - GDSO segment gasoline distribution product margin decreased **6%** in Q2 2025, primarily due to lower sales volume and a reduced site count year-over-year[232](index=232&type=chunk) - SG&A expenses increased by **$2.4 million (3%)** in Q2 2025, driven by wages, benefits, and professional fees, partially offset by lower expenses related to the Revere Terminal sale[239](index=239&type=chunk) [Liquidity and Capital Resources](index=60&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity is supported by operations and credit facilities, with working capital decreasing and significant debt refinancing activities undertaken - Working capital decreased by **$19.3 million** from year-end 2024 to **$187.9 million** at June 30, 2025, mainly due to a **$98.5 million** decrease in inventories and an **$80.4 million** increase in accounts payable[251](index=251&type=chunk) 2025 Capital Expenditure Outlook | Category | Expected 2025 Capex | | :--- | :--- | | Maintenance | $60.0 million - $70.0 million | | Expansion (ex-acquisitions) | $65.0 million - $75.0 million | - On June 23, 2025, the Partnership issued **$450.0 million** of 7.125% senior notes due 2033 and used the proceeds to redeem **$360.3 million** of its 2027 notes, resulting in a **$2.8 million** loss on early extinguishment of debt[286](index=286&type=chunk)[287](index=287&type=chunk)[288](index=288&type=chunk) - As of June 30, 2025, the Partnership had **$1.13 billion** in remaining availability under its credit facilities, subject to borrowing base limitations[280](index=280&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=64&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The Partnership faces interest rate risk from variable debt and commodity price risk managed by derivatives, with a 10% price change impacting derivatives by **$45.0 million** - The company is exposed to interest rate risk on its **$286.7 million** of variable rate debt, where a **1%** increase in interest rates would raise annual interest expense by about **$2.9 million**[302](index=302&type=chunk) Commodity Derivative Sensitivity Analysis (in thousands) | Derivative Type | Fair Value at June 30, 2025 | Effect of 10% Price Increase | Effect of 10% Price Decrease | | :--- | :--- | :--- | :--- | | Exchange traded | ($28,648) | ($26,324) | $26,324 | | Forward contracts | $4,251 | ($18,698) | $18,698 | | **Total** | **($24,397)** | **($45,022)** | **$45,022** | [Item 4. Controls and Procedures](index=66&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal controls - The Principal Executive Officer and Principal Financial Officer concluded that the company's disclosure controls and procedures were effective as of June 30, 2025[312](index=312&type=chunk) - No material changes to the internal control over financial reporting occurred during the quarter ended June 30, 2025[313](index=313&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=67&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in routine legal proceedings not expected to have a material adverse impact on its financial condition - The company does not believe it is a party to any litigation that will have a material adverse impact on its financial condition or results of operations, with details provided in Note 15[151](index=151&type=chunk)[316](index=316&type=chunk) [Item 1A. Risk Factors](index=67&type=section&id=Item%201A.%20Risk%20Factors) No material changes occurred to the risk factors previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2024 - The report refers to the risk factors discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, for a detailed discussion of potential risks[317](index=317&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=67&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company repurchased **58,367** common units during Q2 2025 under its LTIP, with over **1 million** units remaining authorized for repurchase Common Unit Repurchases (Q2 2025) | Period | Units Purchased | Average Price Paid ($) | | :--- | :--- | :--- | | April 2025 | — | — | | May 2025 | 33,367 | — | | June 2025 | 25,000 | $53.21 | - The repurchase program is for meeting obligations under the LTIP and employment agreements, with **1,001,654** units remaining authorized for repurchase as of August 7, 2025[318](index=318&type=chunk) [Item 5. Other Information](index=67&type=section&id=Item%205.%20Other%20Information) The COO adopted a Rule 10b5-1 trading plan on March 25, 2025, for the sale of up to **44,994** common units - Mark A. Romaine, the company's COO, adopted a Rule 10b5-1 trading plan on March 25, 2025, for the sale of up to **44,994** common units[320](index=320&type=chunk) [Item 6. Exhibits](index=67&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including officer certifications and XBRL data files - Lists various filed exhibits, including certifications under Rule 13a-14(a)/15d-14(a) and Section 1350, as well as Inline XBRL documents[321](index=321&type=chunk)[323](index=323&type=chunk)

Financial Data and Key Metrics Changes - For Q2 2025, net income increased by 8%, adjusted EBITDA increased by 7%, and adjusted DCF increased by 9% year-over-year [5] - Net income for Q2 2025 was $25.2 million compared to $46.1 million in Q2 2024, while adjusted EBITDA was $98.2 million compared to $121.1 million in the same period [9] - Adjusted DCF for Q2 2025 was $52.3 million compared to $74.2 million in Q2 2024 [9] Business Line Data and Key Metrics Changes - GDSO product margin decreased by $13.6 million to $207.9 million due to lower site count and adverse weather conditions [10] - Gasoline distribution product margin decreased by $9.4 million to $137.9 million, reflecting lower fuel volumes [10] - Station operations product margin decreased by $4.2 million to $70 million, impacted by weather and lower site count [10] Market Data and Key Metrics Changes - The wholesale segment's product margin was $91.7 million, with gasoline and gasoline blend stocks decreasing by $11.6 million to $58.8 million [11] - Product margin from distillates and other oils increased by $11.4 million to $32.9 million due to favorable market conditions [12] Company Strategy and Development Direction - The company is focused on operational excellence, disciplined capital allocation, and delivering consistent returns for unitholders [16] - Recent terminal acquisitions have expanded the company's reach and strengthened its presence in key markets, establishing a stronger platform for long-term value [6] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of adverse weather conditions on performance, particularly in May and early June [20] - The company is satisfied with its current site portfolio and anticipates minimal further rationalization [23] Other Important Information - The company approved a quarterly cash distribution of $0.75 per unit, marking the fifteenth consecutive increase [6] - The company completed a private offering of $450 million senior unsecured notes to strengthen its balance sheet and extend its debt maturity profile [14] Q&A Session Summary Question: Can you quantify the impact of weather on the quarter? - Management noted that the weather had a material impact, particularly in May, but did not provide an exact number [20][22] Question: How close is the company to completing site rationalization? - Management indicated that they are very satisfied with the current site count and expect minimal further changes [23][25] Question: Is the strength in CPG tied to terminal acquisitions? - Management clarified that the strength is independent of terminal acquisitions and is more related to supply advantages and vertical integration [26] Question: What is the acquisition outlook? - Management stated that bid-ask spreads are wide on the terminaling side, but the retail side remains active with potential opportunities [29]

[Overview of Second Quarter 2025 Performance](index=1&type=section&id=Overview%20of%20Second%20Quarter%202025%20Performance) [CEO Commentary](index=1&type=section&id=CEO%20Commentary) The CEO highlighted solid year-over-year growth in earnings and cash flow for the first half of 2025, attributing it to a diversified asset base and disciplined execution First Half 2025 Year-over-Year Growth | Metric | YoY Growth | | :--- | :--- | | Net Income | 8% | | Adjusted EBITDA | 7% | | Adjusted DCF | 9% | - The company is pleased with the second-quarter performance of its retail, terminal, and wholesale liquid energy portfolio[4](index=4&type=chunk) - The strategic acquisition of key terminals has expanded the company's reach and enhanced its market presence[4](index=4&type=chunk) [Financial Highlights](index=1&type=section&id=Financial%20Highlights) Global Partners reported a decline in key profitability metrics for the second quarter of 2025 compared to the same period in 2024, impacted by a **$2.8 million** loss on the early extinguishment of debt Q2 2025 vs. Q2 2024 Financial Metrics (in millions, except per unit data) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Net Income | $25.2 | $46.1 | | Diluted EPS | $0.55 | $1.10 | | EBITDA | $95.7 | $118.8 | | Adjusted EBITDA | $98.2 | $121.1 | | Distributable Cash Flow (DCF) | $52.0 | $73.1 | | Adjusted DCF | $52.3 | $74.2 | | Gross Profit | $272.4 | $287.9 | - All reported non-GAAP financial measures for Q2 2025 include a **$2.8 million** loss on the early extinguishment of debt related to the redemption of the Partnership's **7.00%** senior notes due 2027[7](index=7&type=chunk) [Segment Performance](index=2&type=section&id=Segment%20Performance) In Q2 2025, the Wholesale segment's product margin remained stable, while the GDSO segment saw a decrease due to lower site count, with overall sales increasing to **$4.6 billion** driven by Wholesale volume Q2 2025 vs. Q2 2024 Product Margin by Segment (in millions) | Segment | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | GDSO | $207.9 | $221.5 | | Wholesale | $91.7 | $91.9 | | Commercial | $6.1 | $6.2 | Q2 2025 vs. Q2 2024 Sales and Volume by Segment | Segment | Sales (Q2 2025) | Sales (Q2 2024) | Volume (Q2 2025) | Volume (Q2 2024) | | :--- | :--- | :--- | :--- | :--- | | Wholesale | $3.1B | $2.6B | 1.5B gal | 1.1B gal | | GDSO | $1.2B | $1.5B | 382.4M gal | 407.0M gal | | Commercial | $275.8M | $280.9M | 141.9M gal | 119.5M gal | | **Total** | **$4.6B** | **$4.4B** | **2.0B gal** | **1.6B gal** | - The decline in GDSO product margin from both gasoline distribution and station operations was partly attributed to a decreased site count year-over-year[10](index=10&type=chunk) [Recent Developments](index=2&type=section&id=Recent%20Developments) The company completed a **$450 million** senior unsecured notes offering due 2033 to refinance debt and announced a quarterly cash distribution of **$0.7500 per common unit** - Completed an upsized private offering of **$450 million** of **7.125%** senior unsecured notes due 2033[15](index=15&type=chunk) - Net proceeds were used to purchase outstanding **$400 million** **7.00%** senior notes due 2027 and to repay a portion of borrowings under its credit agreement[15](index=15&type=chunk) - Announced a quarterly cash distribution of **$0.7500 per common unit** (**$3.00 annualized**), payable on August 14, 2025[15](index=15&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) [Consolidated Statements of Operations](index=6&type=section&id=Consolidated%20Statements%20of%20Operations) For Q2 2025, Global Partners reported total sales of **$4.63 billion** and net income of **$25.2 million**, a decrease from **$46.1 million** in Q2 2024, while six-month net income increased to **$43.9 million** Income Statement Highlights (in thousands, except per unit data) | Metric | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Sales | $4,626,925 | $4,409,698 | $9,219,122 | $8,555,090 | | Gross Profit | $272,362 | $287,884 | $527,603 | $503,019 | | Operating Income | $60,066 | $83,869 | $115,953 | $109,705 | | Net Income | $25,210 | $46,149 | $43,894 | $40,547 | | Diluted Net Income per Unit | $0.55 | $1.10 | $0.92 | $0.73 | [Consolidated Balance Sheets](index=7&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2025, Global Partners had total assets of **$3.78 billion** and total liabilities of **$3.10 billion**, with cash and cash equivalents increasing to **$16.1 million** Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $16,097 | $8,208 | | Total current assets | $1,215,163 | $1,207,380 | | Total assets | $3,784,338 | $3,788,198 | | Total current liabilities | $1,027,264 | $1,000,121 | | Senior notes | $1,270,916 | $1,186,723 | | Total liabilities | $3,098,033 | $3,071,585 | | Partners' equity | $686,305 | $716,613 | [Non-GAAP Financial Measures and Reconciliations](index=3&type=section&id=Non-GAAP%20Financial%20Measures%20and%20Reconciliations) [Explanation of Non-GAAP Measures](index=3&type=section&id=Explanation%20of%20Non-GAAP%20Measures) The company uses non-GAAP measures like Product Margin, EBITDA, Adjusted EBITDA, DCF, and Adjusted DCF to evaluate core profitability, operational performance, and cash generation for distributions and debt service - Product Margin (product sales minus product costs) is used to measure the core profitability of operations[19](index=19&type=chunk) - EBITDA and Adjusted EBITDA are used to assess financial performance, ability to generate cash, and compliance with debt covenants[20](index=20&type=chunk)[23](index=23&type=chunk) - Distributable Cash Flow (DCF) and Adjusted DCF serve as indicators of the company's success in providing a cash return to limited partners[21](index=21&type=chunk)[24](index=24&type=chunk) [Financial Reconciliations](index=8&type=section&id=Financial%20Reconciliations) The report provides detailed reconciliations, showing Q2 2025 gross profit of **$272.4 million** reconciled to a combined product margin of **$305.7 million**, and net income of **$25.2 million** reconciled to Adjusted EBITDA of **$98.2 million** and Adjusted DCF of **$52.3 million** Q2 2025 Reconciliations (in thousands) | Reconciliation | Starting Value (GAAP) | Ending Value (Non-GAAP) | | :--- | :--- | :--- | | Gross Profit to Product Margin | $272,362 | $305,725 | | Net Income to Adjusted EBITDA | $25,210 | $98,158 | | Net Income to Adjusted DCF | $25,210 | $52,281 | - EBITDA, adjusted EBITDA, DCF and adjusted DCF for Q2 2025 all include a loss on early extinguishment of debt of **$2.8 million**[32](index=32&type=chunk) [Other Information](index=3&type=section&id=Other%20Information) [About Global Partners LP](index=3&type=section&id=About%20Global%20Partners%20LP) Global Partners LP is a Fortune 500 master limited partnership operating **54 liquid energy terminals** and approximately **1,700 retail locations** across the Northeast, Mid-Atlantic, and Texas, trading on the NYSE under the ticker symbol **"GLP"** - A Fortune 500 company operating **54 liquid energy terminals** and approximately **1,700 retail locations**[17](index=17&type=chunk) - Distributes gasoline, distillates, residual oil, and renewable fuels to wholesale, retail, and commercial customers[17](index=17&type=chunk) - Trades on the New York Stock Exchange as a master limited partnership under the ticker symbol **"GLP"**[18](index=18&type=chunk) [Forward-Looking Statements](index=5&type=section&id=Forward-Looking%20Statements) This section contains a standard safe harbor statement, cautioning readers that forward-looking statements are based on current expectations and are subject to significant risks and uncertainties - The press release contains forward-looking statements based on current expectations, which are not guarantees of future performance[26](index=26&type=chunk) - Readers are cautioned about significant risks and uncertainties and are directed to the Partnership's SEC filings (Form 10-K, 10-Q, 8-K) for more details[26](index=26&type=chunk)[27](index=27&type=chunk)

In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved the primary and all key secondary endpoints, including demonstrating improvements in a number of cardiovascular risk factors With these results, Lilly is on track to submit orforglipron to global regulatory agencies by year-end and is making substantial investments to meet anticipated demand at launch INDIANAPOLI ...

Core Insights - Novo Nordisk A/S (NVO) reported Q2 2025 earnings of 97 cents per ADR, surpassing the Zacks Consensus Estimate of 93 cents, and up from 65 cents per ADR in the same quarter last year [1][7] - Revenues reached $11.68 billion, a 13% increase year-over-year in Danish kroner (DKK) and an 18% increase at constant exchange rates (CER), driven by higher sales in Diabetes and Obesity Care, although total revenues fell short of the Zacks Consensus Estimate of $11.79 billion [2][7] Revenue Breakdown - The Diabetes and Obesity Care segment generated sales of DKK 71.94 billion, reflecting a 17% increase. Notably, sales of fast-acting insulin Fiasp decreased by 5%, while NovoRapid sales rose by 26% [4] - Sales of Ozempic reached DKK 31.8 billion, up 15%, while Rybelsus sales were DKK 5.65 billion, down 1%. Victoza sales saw a significant decline of 57% [5][6] - Obesity Care sales (Saxenda and Wegovy) increased by 53% to DKK 20.37 billion, with Wegovy sales growing 75% to DKK 19.53 billion, although growth was impacted by illegal compounded versions in the U.S. market [6][7] Rare Disease Segment - Sales in the Rare disease segment rose by 28% to DKK 4.92 billion, with rare blood disorder products contributing DKK 3.1 billion, up 13%. NovoSeven sales increased by 16% to DKK 2 billion [9] Cost Structure - Sales and distribution costs increased by 19% to DKK 17.53 billion, primarily due to promotional activities for Wegovy in the U.S. [10] - Research and development (R&D) costs decreased by 26% to DKK 11.69 billion, mainly due to a prior year impairment loss, despite increased investment in late-stage clinical studies [11] Outlook Revision - Novo Nordisk revised its 2025 sales growth outlook to 8-14%, down from 13-21%, and operating profit growth to 10-16%, down from 16-24%, reflecting weaker-than-expected momentum for key drugs Wegovy and Ozempic [12][13] - The company cited challenges from unregulated compounded GLP-1 alternatives and slower-than-expected uptake of Wegovy in the U.S. market [13][14] Competitive Landscape - Novo Nordisk's global diabetes market share declined by 1.4% to 32.6%, attributed to increased competition from Eli Lilly's tirzepatide products [15] - Despite the competitive pressure, Novo Nordisk aims to maintain a market share of over one-third by 2025 [15] Future Prospects - The company is optimistic about increasing Wegovy sales in the second half of 2025 through initiatives like NovoCare Pharmacy and exclusive formulary coverage with CVS [19] - Ongoing FDA reviews for expanded indications of semaglutide drugs and other pipeline candidates are expected to bolster future revenues [17][18]

Core Insights - The article emphasizes the investment philosophy focused on small cap companies, highlighting the importance of identifying mispriced securities through understanding financial drivers and utilizing DCF model valuation [1] Group 1 - The investment strategy is not confined to traditional categories such as value, dividend, or growth investing, but rather considers all prospects of a stock to assess risk-to-reward [1]

The last time I covered Hims & Hers Health, Inc. (NYSE: HIMS ), the company was branching out a lot. They looked for a solid expansion into European markets via ZAVA and were rapidly pushing for new I'm a retired Wall Street PM specializing in TMT; since kickstarting my career, I've spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of '08, and, more recently, with the AI boom. In one word, what I'd like my service ...

Analyst's Disclosure:I/we have a beneficial long position in the shares of NVO, MCD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I have been investing in Novo Nordisk ( NVO ) since it was trading at $80 per share. Back then I thought I was getting a bargain, and despi ...